Clinical Research
Filter News
Found 101,363 articles
-
Early Clinical Data Suggests Nearly 2X Prolonged Median Survival for Inoperable, Locally Advanced Pancreatic Cancer with MRIdian MR-Guided Radiation Therapy
10/17/2017
ViewRay announced today outcomes data presented during the recent 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO).
-
Anpac Bio Surpasses 50,000 Case Study Milestone
10/17/2017
Dr. Chris Yu, CEO of international life sciences corporation Anpac Bio, announced this week the company set a new, international record, processing and reporting over 50,000 cases worldwide of the company's proprietary, "Cancer Differentiation Analysis" (CDA) liquid biopsy tests.
-
Invitae data shows increased diagnosis rates with custom NGS technique allowing simultaneous genetic sequencing and copy number variant detection
10/17/2017
Invitae is presenting data showing genetic sequencing and copy number variant (CNV) detection performed together using expert-curated panels offers better diagnosis rates over sequencing alone in patients with neuromuscular disorders and childhood epilepsy.
-
UZ Leuven Treats First Patient in Europe on Varian Halcyon Cancer Treatment System
10/17/2017
Variantoday announced an 80-year-old male with head & neck cancer became the first patient in Europe to be treated on the Halcyon system at University Hospitals Leuven in Belgium.
-
Children’s Hospital Los Angeles Release: A Liquid Biopsy For Retinoblastoma Developed By Children’s Hospital Los Angeles And Keck Medicine Of USC
10/17/2017
Retinoblastoma is a tumor of the retina that generally affects children under 5 years of age. If not diagnosed early, retinoblastoma may result in loss of one or both eyes and can be fatal. Unlike most cancers that are diagnosed using a biopsy, retinoblastoma tumors cannot be directly biopsied.
-
Akcea Presents Data Demonstrating Significant Burden of Illness in Familial Chylomicronemia Syndrome
10/16/2017
New data from the global IN-FOCUS study were presented at the NORD Rare Diseases and Orphan Products Breakthrough Summit in Washington, D.C.
-
Prime Therapeutics Study Finds A Diabetes Drugs Value Based Insurance Design Improves Adherence, Doesn't Lower Total Cost Of Care
10/16/2017
-
Takeda Release: New Post-Hoc Analyses Report Early Symptomatic Improvement In Moderately To Severely Active Ulcerative Colitis Or Crohn's Disease Patients Taking Entyvio (Vedolizumab), Particularly In Biologic-Naïve Patients
10/16/2017
Takeda today announced the presentation of data suggesting early symptomatic improvement in specific symptoms with Entyvio (vedolizumab) in patients with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD), particularly in biologic-naïve patients for whom other therapies have not worked well enough.
-
Creative Medical Technology Holdings Expands Stem Cell Therapeutic Platform By Entry Into Field Of Stroke And Neurodegeneration
10/16/2017
Creative Medical Technology Holdings announced today filing of a patent application using a combination of an FDA approved drug together with the patient's own bone marrow derived stem cells for the treatment of stroke.
-
Enzyvant Initiates Farber Disease Natural History Study
10/16/2017
Enzyvant, a biopharmaceutical company focused on developing innovative treatments for patients with rare diseases, today announced the initiation of the Farber Disease Natural History Study.
-
Regen BioPharma Researchers Capitalize on Key Structure in Compounds that Activate Checkpoint NR2F6 for the Potential Treatment of Autoimmune Diseases
10/16/2017
Regen BioPharma and (OTCQB: RGBPP) believes it has taken full advantage of its recent prior discovery in developing small molecule drugs that activate NR2F6.
-
A*STAR Release: Scientists Uncover A New Layer Of Complexity Beyond The Human Genome
10/16/2017
Singaporean researchers have made significant inroads in the study of Ribonucleic Acid (RNA) editing.
-
Leader of Johnson & Johnson 3D Printing Center of Excellence Outlines Advantages of Customized Knee Implants
10/16/2017
ConforMIS has obtained additional positive clinical data regarding the performance of its customized partial knee replacement implants.
-
PacBio's Recent Projects Highlight Success of SMRT Sequencing for Characterizing Structural Variation in Human Genomes
10/16/2017
A series of publications and initiatives from the genomics community demonstrates the rapid adoption of Single Molecule, Real-Time Sequencing for discovering structural variants throughout the human genome
-
Soft Suit Exoskeleton Technology Begins Next Phase Of Testing In Pre-Clinical Study
10/16/2017
ReWalk today announced that the soft exosuit technology currently in development has entered the next phase of testing and verification in collaboration with researchers at Harvard University's Wyss Institute for Biologically Inspired Engineering.
-
ReWalk Completes Critical Design Review Processes Of Restore System For Move To Clinical Studies
10/16/2017
ReWalk announced today completion of all internal processes to initiate clinical studies and the initial production of its "soft suit" exoskeleton design for stroke patients.
-
ChemPass And LifeArc Report Positive Results In The Validation of ChemPass Technology In Medicinal Chemistry Programs
10/16/2017
ChemPass announced today that they have successfully completed the first phase of their evaluation of ChemPass' technology for its ability to support LifeArc's medicinal chemistry programs.
-
The FDA’s Cellular, Tissue and Gene Therapies Advisory Committee unanimously recommended Spark's Luxturna in a vote of 16 to 0.
-
DNA Study Provides Insight Into How To Live Longer, University of Edinburgh Reveals
10/13/2017